Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Donanemab puts brakes on Alzheimer’s disease progression
In the treatment of individuals with early symptomatic Alzheimer's disease and amyloid and tau pathology, the immunoglobulin G1 monoclonal antibody donanemab helps slow clinical progression, according to the results of the phase III TRAILBLAZER-ALZ 2 study.
Donanemab puts brakes on Alzheimer’s disease progression
26 Jul 2023
SG data: Booster mRNA vax shots shield cancer-affected individuals from COVID-19
Administration of booster doses of mRNA-based vaccines provide protection against COVID-19 and its adverse outcomes in patients with cancer who are actively receiving treatment as well as in cancer survivors, as shown in a study from Singapore.
SG data: Booster mRNA vax shots shield cancer-affected individuals from COVID-19
25 Jul 2023
Vedolizumab lowers risk of severe CDI in patients with ulcerative colitis
Treatment with vedolizumab is associated with a reduced adjusted risk of severe Clostridioides difficile infection (CDI), but not total CDI, in patients with ulcerative colitis (UC), reports a study. Additionally, cytomegalovirus colitis (CMVC) is not seen in those who initiated vedolizumab.
Vedolizumab lowers risk of severe CDI in patients with ulcerative colitis
25 Jul 2023
Does ribavirin improve efficacy of SOF/VEL/VOX in HCV retreatment?
The combination of sofosbuvir, velpatasvir, and voxilaprevir (SOF/VEL/VOX) with or without ribavirin demonstrates efficacy for the retreatment of patients with hepatitis C virus (HCV) infection in whom prior direct-acting antiviral (DAA) treatment has failed, a study in Egypt has shown.
Does ribavirin improve efficacy of SOF/VEL/VOX in HCV retreatment?
24 Jul 2023
Prolonged-release pirfenidone shows therapeutic potential in post–COVID-19 pulmonary fibrosis
A 3-month course of prolonged-release pirfenidone formulation appears to be safe and efficacious in the treatment of patients with postacute sequelae of COVID-19 (PASC)-pulmonary fibrosis, as shown in a study.
